In the last trading session, 1.29 million Corvus Pharmaceuticals Inc (NASDAQ:CRVS) shares changed hands as the company’s beta touched 0.57. With the company’s per share price at $3.86 changed hands at -$0.14 or -3.50% during last session, the market valuation stood at $297.66M. CRVS’s last price was a discount, traded about -159.07% off its 52-week high of $10.00. The share price had its 52-week low at $1.75, which suggests the last value was 54.66% up since then. When we look at Corvus Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.62 million shares, with the 3-month average coming to 1.17 million.
Analysts gave the Corvus Pharmaceuticals Inc (CRVS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRVS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
Instantly CRVS was in red as seen at the end of in last trading. With action -11.06%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 106.42%, with the 5-day performance at -11.06% in the red. However, in the 30-day time frame, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) is 2.12% up. Looking at the short shares, we see there were 7.94 million shares sold at short interest cover period of 9.84 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need an upside of 64.91% from its current market value. According to analyst projections, CRVS’s forecast low is 11 with 11 as the target high. To hit the forecast high, the stock’s price needs a -184.97% plunge from its current level, while the stock would need to soar -184.97% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 8.47%. The 2025 estimates are for Corvus Pharmaceuticals Inc earnings to increase by 62.75%, but the outlook for the next 5-year period is at 14.69% per year.
CRVS Dividends
Corvus Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-May-08.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.83% of Corvus Pharmaceuticals Inc shares while 49.05% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 51.00%. There are 49.05% institutions holding the Corvus Pharmaceuticals Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 11.6289% of the shares, roughly 6.94 million CRVS shares worth $12.64 million.
SAMLYN CAPITAL, LLC holds the second largest percentage of outstanding shares, with 10.2546% or 6.12 million shares worth $11.14 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 1.62 shares estimated at $6.26 million under it, the former controlled 2.38% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 1.16% of the shares, roughly 793.14 shares worth around $3.06 million.
